India’s Drug Regulator SEC Approves Russia’s Sputnik V for Emergency Use

No Comments
Posted in Featured, National, Northeast

The Centre on Monday granted approval to Russia’s coronavirus vaccine Sputnik-V for restricted use in India, as per sources within the drug regulator’s office.

Developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin.

The Russian jab has an efficacy rate of 91.6% and is carrying out its phase-3 clinical trials in Belarus, UAE, India, and Venezuela, according to Sputnik-V’s website.

Tags: , , ,

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

More Articles